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Background: TFAP4 is a transcription factor that controls cell proliferation, stemness and epithelial-mesenchymal transi-
tion and is up-regulated in colorectal cancer.
Results:TFAP4 is targeted for degradation by the SCFTrCP ubiquitin ligase. Failure to degradeTFAP4 leads to aberrantmitosis.
Conclusion: TFAP4 degradation is required for the fidelity of mitosis.
Significance:Misregulation of TFAP4 might contribute to genomic instability and tumorigenesis.
TFAP4, a basic helix-loop-helix transcription factor that reg-
ulates the expression of a multitude of genes involved in the
regulation of cellular proliferation, stemness, and epithelial-
mesenchymal transition, is up-regulated in colorectal cancer
and a number of other human malignancies. We have found
that, during the G2 phase of the cell division cycle, TFAP4 is tar-
geted for proteasome-dependent degradation by the SCFTrCP
ubiquitin ligase. This event requires phosphorylation ofTFAP4on
a conserved degron. Expression of a stable TFAP4 mutant unable
to interact with TrCP results in a number of mitotic defects,
including chromosome missegregation and multipolar spindles,
which eventually lead to the activation of the DNA damage
response. Our findings reveal thatTrCP-dependent degradation
of TFAP4 is required for the fidelity of mitotic division.
Transcription factor activating enhancer-binding protein 4
(TFAP4)3 is a ubiquitously expressed basic helix-loop-helix leu-
cine-zipper transcription factor that binds to the consensus
E-box sequence 5-CAGCTG-3 (1). It has been reported that
TFAP4 controls the expression of numerous genes regulating
cell proliferation (2, 3). TFAP4 target genes also include stem
cell markers such as LGR5 and regulators of epithelial-mesen-
chymal transition such as SNAIL and E-cadherin (2, 3). Impor-
tantly, TFAP4 protein levels have been found elevated in
human colorectal, hepatocellular, and gastric carcinoma (3–5).
Despite the described role of TFAP4 in cancer, the molecular
mechanisms controlling TFAP4 protein levels and the post-
translational modifications regulating TFAP4 stability are cur-
rently unknown.
In the present study,we identifyTFAP4 as a new interactor of
the F-box proteinTrCP (-transducin repeat-containing pro-
tein) in a mass spectrometry-based screen aimed at the identi-
fication of substrates of SCFTrCP, a multisubunit Cullin-RING
ubiquitin ligase composed of a cullin scaffold, Cul1, the adaptor
protein Skp1, and the RING subunit Rbx1. It is well established
that, through its WD40 repeats, TrCP recognizes a diphos-
phorylated motif with the consensus DpSGX(X)pS in which
the serine residues are phosphorylated to allow binding to
TrCP (6). Notably, work by several groups has demonstrated
that SCFTrCP plays a fundamental role in the regulation of
many cellular processes that are related to cancer through tar-
geted destruction of its specific substrates (7, 8).
We also show that during the G2 phase of the cell cycle,
SCFTrCP targets TFAP4 for proteasomal degradation and
demonstrate that defective degradation of TFAP4 results in
aberrant mitotic divisions and chromosome missegregation,
which lead to the activation of the DNA damage checkpoint.
EXPERIMENTAL PROCEDURES
Cell Culture, Synchronization, and Drug Treatment—HeLa,
HEK293T, 293GP2, U2OS, hTERT-RPE1, DLD1, and HCT116
cells were maintained in Dulbecco’s modified Eagle’s medium
(Invitrogen) containing 10% fetal calf serum.HeLa and hTERT-
RPE1 cells were synchronized at G1/S by thymidine treatment
as described (9). DLD1 cells were synchronized at the G1/S
transition by using FBS-depleted medium for 32 h followed by
treatment with aphidicolin (2 g/ml) for another 24 h. The
following drugs were used: nocodazole (0.1 g/ml) to arrest
cells in prometaphase, MG132 (10 M) to inhibit the protea-
some, cycloheximide (100 g/ml) to block protein synthesis
and doxycycline (1 g/ml) to induce the expression of TFAP4
(wild type or mutants).
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Biochemical Methods—Immunoprecipitation and immuno-
blotting were performed by standard methods and have been
described previously (10–12).
Purification of TrCP2 Interactors—HEK293T cells were
transfected with pcDNA3-FLAG-HA-TrCP2 or pcDNA3-FLAG-
HA-TrCP2(R447A) and treated with 10 M MG132 for 6 h.
Cells were harvested and subsequently lysed in lysis buffer (50
mMTris-HCl, pH 7.5, 150mMNaCl, 1mMEDTA, 0.5%Nonidet
P-40, plus protease and phosphatase inhibitors). TrCP2 was
immunopurified with anti-FLAG agarose resin (Sigma-Aldrich).
After washing, proteins were eluted by competition with FLAG
peptide (Sigma-Aldrich). The eluate was then subjected to a sec-
ond immunopurification with anti-HA resin (12CA5monoclonal
antibodycross-linked toproteinG-Sepharose; Invitrogen)prior to
elution in Laemmli sample buffer. The final eluate was separated
by SDS-PAGE, and proteins were visualized by Coomassie colloi-
dal blue. Bands were sliced out from the gels and subjected to
in-gel digestion. Gel pieces were then reduced, alkylated, and
digested according to a published protocol (13). For mass spec-
trometric analysis, peptides recovered from in-gel digestion
were separated with a C18 column and introduced by nano-
electrospray into the LTQOrbitrap XL (Thermo Fisher) with a
configuration as described (14). Peak lists were generated from
the MS/MS spectra using MaxQuant build (version 1.0.13.13)
(15) and then searched against the IPIHumandatabase (version
3.37, 69164 entries) using Mascot search engine (Matrix Sci-
ence). Carbaminomethylation (57 Da) was set as fixed modi-
fication, and protein N-terminal acetylation and methionine
oxidation were set as variable modifications. Peptide tolerance
was set to 7 ppm, and fragment ion tolerance was set to 0.5 Da,
allowing two missed cleavages with trypsin enzyme. Finally,
Scaffold (version Scaffold_3.6.1, Proteome Software, Inc.) was
used to validate MS/MS-based peptide and protein identifica-
tions. Peptide identifications were accepted if their Mascot
scores exceeded 20.
Antibodies—Mouse monoclonal antibodies were from Invit-
rogen (Cul1), Sigma-Aldrich (FLAG, -tubulin FITC conjugate),
Santa Cruz Biotechnology (actin), BD Biosciences (-catenin),
Covance (HA), andNovus Biologicals (TFAP4). Rabbit polyclonal
antibodies were from Cell Signaling (TrCP1), Bethyl Laborato-
ries (PDCD4), Millipore (REST, phospho-histone H3 (Ser-10)),
Sigma-Aldrich (FLAG), Santa Cruz Biotechnology (cyclin A, HA,
and Skp1).
Plasmids—TFAP4 mutant was generated using the QuikChange
site-directed mutagenesis kit (Stratagene). For retrovirus pro-
duction, both wild type TFAP4 and the non-degradable TFAP4
mutant were subcloned into the retroviral vector LZRSpBMN-
GFP. For producing lentiviruses, both wild type TFAP4 and the
TFAP4 mutant were subcloned into the lentiviral vector
pHAGE2-EF1. Enhanced green fluorescent protein-labeled
histone H2B was cloned into pEGFP-N1 vector. To generate
the fluorescent ubiquitylation-based cell cycle indicator
(FUCCI) cells, the constructs pCSII-EF-mKO2-hCdt1(30/
120) and pCSII-EF-mAG-hGEM(1/110) were used. For sta-
ble transfection, wild type TFAP4 and TFAP4(E135A/
S139A) were subcloned into pcDNA 4/TO inducible vector.
All cDNAs were sequenced.
Transient Transfections and Retrovirus- and Lentivirus-me-
diated Gene Transfer—HEK293T cells were transfected using
the calcium phosphatemethod as described (11). HCT116 cells
were transfectedwithLipofectamine according to themanufactu-
rer’s instructions. Retrovirus-mediated gene transfer was
describedpreviously (11, 12). For lentivirusproduction,HEK293T
cells were co-transfectedwith pHAGE2-EF1 and packaging vec-
tors by using polyethylenimine. Virus-containing medium was
collected 48 h after transfection and supplemented with 8 g/ml
polybrene. Cells were incubated with virus-containing medium
for 6 h for 2 consecutive days.
Gene Silencing by Small Interfering RNA—The sequences
and validation of the oligonucleotides corresponding to TrCP1
and TrCP2 were described previously (9, 16, 17). Cells were
transfectedwith the oligonucleotides twice (24 and 48h after plat-
ing) using Oligofectamine (Invitrogen) according to the manufa-
cturer’s recommendations. Forty-eight hours after the last trans-
fection, lysates were prepared and analyzed by SDS-PAGE and
immunoblotting.
In Vitro Ubiquitylation Assay—SCFTrCP-mediated ubiqui-
tylation assays were described previously (12, 18). Briefly,
TFAP4 ubiquitylation was performed in a volume of 10 l con-
tainingTrCP-TFAP4 immunocomplexes, 50mMTris, pH 7.6,
5mMMgCl2, 0.6mMDTT, 2mMATP, 2l of in vitro-translated
unlabeled TrCP1, 1.5 ng/l E1 (Boston Biochem), 10 ng/l
Ubc3, 2.5 g/l ubiquitin (Sigma), and 1 M ubiquitin alde-
hyde. The reactions were incubated at 30 °C for the indicated
times and analyzed by immunoblotting.
Phosphorylation Analysis by Mass Spectrometry—Samples
were reduced with 10mMDTT for 30min at 60 °C, followed by
addition of iodoacetamide to 20mM followed by a 30-min incu-
bation in the dark at room temperature. The first digestion was
performed using Lys-C for 4 h at 37 °C. Subsequently, the digest
was diluted 5-fold using 50 mM ammonium bicarbonate to a
final urea concentration of 2 M, and a second digestion with
trypsin was performed overnight at 37 °C. Finally, the digestion
was quenched by addition of formic acid to a final concentra-
tion of 0.1% (v/v). The resulting solutionwas desalted using 200
mg Sep-Pak C18 cartridges (Waters Corp.), lyophilized and
reconstituted in 10% formic acid. LC-MS/MS was performed
with both collision-induced dissociation and electron transfer
dissociation in the form of data-dependent decision tree (19,
20). MS spectra to peptide sequence assignment is performed
with Proteome Discoverer (version 1.3), with MASCOT (ver-
sion 2.3) as search engine and the localization of phosphory-
lated sites was evaluated with PhosphoRS (version 2) (21).
Immunofluorescence—Cells were plated and cultured on
coverslips coated with polylysine (Sigma-Aldrich) with com-
plete medium. Cells were fixed and permeabilized in 100%
methanol at 20 °C for 10 min and then incubated with the
primary FITC-conjugated antibody for 1 h at room tempera-
ture in 0.5% Tween 20 in PBS (TBST). Cells were washed three
times in 0.5% TBST. Hoechst 33342 (Sigma-Aldrich) was
included to detect the nuclei. Slides were mounted by using
Vectashield mounting media (Vector Labs).
Live Cell Imaging—Cells were plated and cultured in 24-well
plates in complete medium. Microscope was equipped with an
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Protein Protein ID Unique peptides Total spectra
TFAP4 Q01664 27 231
TrCP2 Q9UKB1 21 30
TrCP1 Q9Y297 8 9
Skp1 P63208 6 8
Cul1 Q13616 3 3
TrCP2 WT TrCP2(R447A)
Unique peptides 6 0
Unique spectra 8 0
Total spectra 10 0
Identified aa/total aa 72/338 0/338
% coverage 21 0
Peptide #1 (R)AVIVKPVR(S) -
Peptide #2 (K)VPSLQHFR(K) -
Peptide #3 (R)LLQQNTQLK(R) -
Peptide #4 (K)VIAQQVQLQQQQEQVR(L) -
Peptide #5 (R)MQSINAGFQSLK(T) -
Peptide #6 (R)QNLDTIVQAIQHIEGTQEK(Q) -
TFAP4 
TFAP4 (Ub)n 
+ + + Cul1-Skp1-Rbx1 
- + + TFAP4 
- + - TrCP1 WT 
- - + TrCP1 F 
FIGURE 1. Immunopurification of TrCP2 and identification of TFAP4 as a putative substrate of SCFTrCP. A, FLAG-tagged wild type TrCP2 or the
TrCP2(R447A) mutant were expressed in HEK293T cells. Forty-eight hours after transfection, cells were treated for 6 h with the proteasome inhibitor
MG132 and then collected and lysed. Whole cell extracts (WCE) were immunoprecipitated with anti-FLAG resin and immunoblotted with antibodies for
the indicated proteins. B, list of unique peptides identified in wild type TrCP2 and TrCP2(R447A) immunopurifications. C and D, HEK293T cells were
transfectedwith an empty vector (EV) or the indicated F-box proteins. Forty-eight hours after transfection, cells were treated for 6 hwith the proteasome
inhibitor MG132 and then collected and lysed. Whole cell extracts were immunoprecipitated with anti-FLAG resin and immunoblotted with anti-TFAP4
and anti-FLAG antibodies. E, HEK293T cells were transfected with an empty vector, the indicated FLAG-tagged F-box proteins (FBPs), CDH1, or CDC20.
Cells were treated as in A. Whole cell extracts were immunoprecipitated with anti-FLAG resin and immunoblotted with antibodies specific for the
indicated proteins. F, list of proteins identified in the immunopurification of FLAG-HA epitope-tagged TFAP4. The number of unique peptides and total
spectra recovered for the indicated proteins are shown. G, in vitro ubiquitylation assay of TFAP4 by immunopurified TrCP. HEK293T cells were
transfected with TFAP4, Skp1, Cul1, and Rbx1 in the absence or presence of either FLAG-tagged TrCP1 or a FLAG-tagged TrCP1(F-box) mutant. After
immunopurification with an anti-FLAG resin, in vitro ubiquitylation of TFAP4 was performed. Samples were analyzed by immunoblotting with an
anti-TFAP4 antibody.
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incubating chamber at 37 °C and a CO2 supply. Images were
taken at 10-min intervals over 24 h.
RESULTS
Structural studies have shown that arginine 474 in theWD40
-propeller of TrCP1 contacts the DpSGX(X)pS destruc-
tion motif of TrCP substrates (22). It has been also reported
that the TrCP1(R474A) mutant is not able to promote polyu-
biquitylation of its substrate IB in an in vitro ubiquitylation
assay (22). We confirmed that the equivalent TrCP2 mutant
(TrCP2(R447A)) does not bind to previously established
TrCP substrates such as -catenin, REST (repressor element-
1-silencing transcription factor), and PDCD4 (programmed
cell death-4), while retaining the ability to interact with the SCF
subunits Cul1 and Skp1 (Fig. 1A). We took advantage of these
properties of TrCP and used a differential immunopurification
strategy followed by mass spectrometry analysis to identify novel
substrates of SCFTrCP.We expressed either wild typeTrCP2 or
the TrCP2(R447A) mutant (both FLAG-HA epitope-tagged at
theN terminus) inHEK293T cells and purifiedTrCP2 immuno-
precipitates, which were then analyzed bymass spectrometry. Six
unique peptides corresponding to the basic helix-loop-helix leu-
cine zipper transcription factor TFAP4 were recovered in wild
type TrCP2 immunoprecipitates, but not in TrCP2(R447A)
immunopurifications (Fig. 1B).
To confirm thebindingbetweenTrCPandTFAP4,we immu-
noprecipitated FLAG-tagged wild type TrCP2 and assessed its
binding to endogenous TFAP4 by immunoblotting. As shown in
Fig. 1C, wild type TrCP2, but not the TrCP2(R447A) mutant,
coimmunoprecipitated with endogenous TFAP4. Similar results
were obtained with TrCP1 (Fig. 1D).
To assess the specificity of theTrCP-TFAP4 interaction,we
immunoprecipitated a number of FLAG epitope-tagged F-box
proteins as well as the related proteins Cdh1 and Cdc20 from
HEK293T cells and analyzed their ability to pull down endoge-
nous TFAP4. TrCP1 and TrCP2 coimmunoprecipitated
with endogenous TFAP4 (Fig. 1E), whereas other members of
the FBXW family of F-box proteins, FBXW2, FBXW4, FBXW5,
FBXW7, FBXW8, or the APC/C activators Cdh1 and Cdc20
(also containing WD40 repeats) did not.
When we immunopurified FLAG-HA epitope-tagged TFAP4,
we recovered unique peptides corresponding to subunits of
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FIGURE 2. A conserved phosphodegron is required for the binding of TFAP4 to TrCP. A, schematic representation of the TrCP-binding motifs in
previously reported substrates of TrCP aligned with the candidate phosphodegron in TFAP4 orthologs. The amino acidic sequence of the double mutant is
shown (bottom). B, TFAP4 Glu-135 and Ser-139 are required for the interaction of TFAP4 with TrCP1. HEK293T cells were transfected with the indicated
HA-tagged proteins. Whole-cell extracts were subjected to immunoprecipitation (IP) with HA-resin, followed by immunoblotting with antibodies specific for
the indicated proteins. Immunoprecipitations of the known TrCP substrate REST (wild type and E1009A/S1013A) are shown as additional controls. C–E,
HA-taggedwild type TFAP4 andTFAP4(E135A/S139A)were expressed inHEK293T (C), HeLa (D), andU2OS (E) cells. Cellswere treatedwith cycloheximide (CHX)
for the indicated times and collected. Proteins were analyzed by immunoblotting with an anti-HA antibody to detect TFAP4 or with an anti-Cul1 antibody to
show loading normalization. The graphs show the quantification of TFAP4 abundance relative to the amount at time 0. F, FLAG-HA-tagged TrCP was
immunoprecipitated from HEK293T cells and analyzed by mass spectrometry. The ion fragmentation spectrum is shown. The TFAP4 tryptic peptide DEGIG-
SPDIWEDEK spanning thephosphodegronwas foundphosphorylatedonSer-139. As shown, peptide sequences canbeexplainedby their respective collision-
induced dissociation MS/MS spectra, including phospho-Ser-139. The diagnostic daughter ions are highlighted with red arrows. EV, empty vector; Hs, Homo
sapiens; Rn, Rattus norvegicus;Mm,Mus musculus; Bt, Bos taurus; Cf, Canis familiaris; Dr, Danio rerio.
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SCFTrCP, i.e. TrCP1 (8), TrCP2 (21), Skp1 (6), and Cul1 (Fig.
1F) (3), further supporting the interaction between TFAP4 and
SCFTrCP.
To testwhether SCFTrCP is directly responsible for the ubiq-
uitylation of TFAP4, we reconstituted TFAP4 ubiquitylation in
vitro. Immunopurified wild type TrCP1, but not TrCP1(F-
box), an inactive mutant that lacks the F-box domain, triggered
efficient ubiquitylation of TFAP4 in vitro (Fig. 1G).
Substrates of SCFTrCP contain a conserved DpSGX(X)pS
degron that mediates the interaction with TrCP (6, 7, 22).
TFAP4 has a modified motif in which the first serine residue is
replaced by glutamic acid as other established substrates of
SCFTrCP (Fig. 2A) (11, 23, 24). We generated a mutant TFAP4
protein in which glutamic acid 135 and serine 139 were substi-
tuted with alanine (Fig. 2A) and examined its ability to interact
with TrCP. The TFAP4(E135A/S139A) mutant did not bind
endogenous TrCP in immunoprecipitation experiments (Fig.
2B) and was markedly stabilized as demonstrated by half-life
experiments carried out in various cell lines (Fig. 2, C–E).
To test whether Ser-139 is phosphorylated in cultured cells,
we purified TrCP2 from HEK293T cells treated with the pro-
teasome inhibitorMG132 and analyzed the phosphorylation of
co-immunoprecipitating TFAP4 by tryptic digestion followed
by phosphopeptide enrichment and LC-MS/MS. Analysis of
the recovered TFAP4 phosphopeptides demonstrated that Ser-
139 is phosphorylated in cells (Fig. 2F).
As it has been reported that TFAP4 controls the expression
of many cell cycle regulators (2, 3), we hypothesized that the
protein levels of TFAP4 might oscillate during cell cycle pro-
gression. To test this hypothesis, we analyzed by immunoblot-
ting the abundance of TFAP4 throughout the cell cycle. HeLa
cells were synchronized at theG1/S transition by double thymi-
dine block before releasing them into freshmedium (to analyze
TFAP4 protein levels in the following S, G2, andM phases) and
in mitosis by the nocodazole block-and-release procedure (Fig.
3, A and B). Synchronization was monitored by immunodetec-
tion of cyclin A (an S/G2 phase protein) and phospho-histone
H3 (a mitotic marker) as well as by flow cytometry (data not
shown).We found that the abundance of TFAP4 oscillates dur-
ing the cell cycle. The levels of TFAP4 decreased in early G2 (at
a time when the levels of cyclin A, which is degraded in early
mitosis, were still elevated), remained low in mitosis and in the
following G1, and increased at G1/S preceding cyclin A up-reg-
ulation. Similar kinetics of TFAP4 decrease in early G2 was
observed in other cell types such as non-transformed hTERT-
immortalized retinal pigment epithelial (hTERT-RPE1) cells
(Fig. 3C) and DLD1 cells (Fig. 3D). The proteasome inhibitor
MG132 prevented the disappearance of TFAP4 in HeLa cells
arrested in prometaphase, indicating that the degradation of
TFAP4 in G2 is mediated by the proteasome (Fig. 3E).
To test whether the degradation of TFAP4 is mediated by
TrCP, we silenced the expression of both TrCP1 and
TrCP2 by RNAi (18, 25) in HeLa cells. Fig. 3F shows that the
knockdown of TrCP caused accumulation of TFAP4 in pro-
metaphase, whereas it had no effect in cells arrested atG1/S and
a moderate effect in asynchronous cells.
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mitotic spindle aberrations. A, cells expressing wild type TFAP4 or the TFAP4(E135A/S139A) mutant were treated with nocodazole for the indicated times.
Cells were lysed and analyzed by immunoblotting with antibodies for the indicated proteins. B, HCT116 cells, transduced with FUCCI vectors and expressing
either wild type TFAP4 or the non-degradable TFAP4(E135A/S139A) mutant, were analyzed by time-lapse imaging. Phase contrast images and fluorescent
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To pinpoint whenTrCP targets TFAP4 for proteasome-de-
pendent degradation, TrCP-silenced cells were released from
a thymidine block and collected at different time points. As
shown in Fig. 3G, the knockdown of TrCP prevented the
destruction of TFAP4 occurring 	4–6 h after cells were
released from the thymidine block.
To study the function of theTrCP-mediated degradation of
TFAP4 during cell cycle, we transduced cells with lentiviruses
expressing wild type TFAP4 and the degradation-resistant
TFAP4(E135A/S139A)mutant. Cells approachingmitosiswere
then analyzed by immunoblotting (Fig. 4A). As expected,
although levels of wild type TFAP4 decreased as cells moved
toward mitosis, levels of the TFAP4(E135A/S139A) mutant
remained unchanged. Moreover, compared with cells express-
ing wild type TFAP4, cells expressing the non-degradable
TFAP4 mutant displayed a slower kinetics of mitotic entry as
indicated by the phosphorylation of histone H3 on Ser-10.
To examine whether the latemitotic entry of cells expressing
the non-degradable TFAP4 mutant was caused, at least in part,
by a delay in G2 progression, we employed FUCCI (26) live cell
imaging. This system is based on the expression of both a red
(RFP) and green (GFP) fluorescent protein fused to Cdt1 and
geminin, respectively. Based on the fact that Cdt1-RFP is tar-
geted for degradation in G2 by the SCFSkp2 ubiquitin ligase and
geminin-GFP is degraded in lateM and early G1 by APC/CCdh1,
cells are red in G1, become yellow upon entry in S phase (where
both fusion proteins are present), are green throughout S and
G2, and are colorless at the end of mitosis. We generated stable
transfectants of HCT116-FUCCI cells in which the expression
of TFAP4 (wild type or TFAP4(E135A/S139A)) could be
pulsed-induced by doxycycline. These cells were then analyzed
by live cell imaging. As shown in Fig. 4,B andC, cells expressing
wild type TFAP4 and the TFAP4(E135A/S139A) mutant dis-
played a similar Cdt1-positiveG1 phase; however, cells express-
ing the non-degradable TFAP4(E135A/S139A)mutant showed
a prolonged geminin-positive S/G2 (9.9 h) when comparedwith
cells expressing wild type TFAP4 (6.8 h).
In the course of our experiments, we observed that the expres-
sion of the non-degradable TFAP4(E135A/S139A) mutant in
HCT116 cells,whichhave a relatively stable karyotype, resulted in
notable nuclear atypia, including lobulated and enlarged nuclei
(Fig. 4, D and E). This phenotype becomes increasingly pene-
trant with longer time of doxycycline treatment (which triggers
the expression of wild type TFAP4 or TFAP4(E135A/S139A)),
eventually occurring in virtually all cells. Notably, although less
pronounced, nuclear atypia was also present in cells overex-
pressing wild type TFAP4.
To test whether these cellular abnormalities were caused by
defective mitotic divisions, we expressed wild type TFAP4 and
the non-degradable TFAP4(E135A/S139A)mutant in HCT116
cells expressing enhanced green fluorescent protein-labeled
histone H2B, which were then analyzed by time-lapse micros-
copy. We found that cells expressing TFAP4(E135A/S139A)
displayed chromosome missegregation (Fig. 4F). The percent-
age of mitotic cells with chromosome missegregation was 28%
(n
 100) for the non-degradable TFAP4 and 14% (n
 100) for
wild type TFAP4. In addition, HCT116 cells expressing
TFAP4(E135A/S139A) displayed a number of mitotic spindle
abnormalities, including the formation of multipolar spindles,
as judged by-tubulin andHoechst staining. The percentage of
mitotic cells with multipolar spindles was	30% (n
 300) for
the degradation-resistant TFAP4 mutant and close to 10%
(n 
 300) for wild type TFAP4. Examples of mitoses with
multipolar spindles in HCT116 and hTERT-RPE1 cells are
shown in Figs. 4G.
Notably, the expression of the degradation-resistant
TFAP4(E135A/S139A) mutant intensified the phenotypes
observed in cells expressing wild type TFAP4, likely as a result
of the persistence of TFAP4 expression in G2 rather than
TFAP4 overexpression. In fact, the same mitotic aberrations
and nuclear defects were also observed when TFAP4(E135A/
S139A) was expressed at moderate levels in a retroviral vector
(Fig. 4H).
It has been shown that missegregating chromosomes are
often damaged during cytokinesis, triggering a DNA double-
strand break response (27). The observed chromosome segre-
gation errors in cells expressing the degradation-resistant
TFAP4 mutant (Fig. 4, D–G), as well as their slower kinetics of
mitotic entry and prolonged progression through G2 (Fig. 4,
A–C) prompted us to test whether failure to degrade TFAP4
results in the activation of the G2 DNA damage checkpoint. As
shown in Fig. 4I, expression of the TFAP4(E135A/S139A)
mutant leads to accumulation of p53 and phosphorylation of
Chk2 on threonine 68, two markers of damaged DNA, indicat-
ing that stabilizingmutations of TFAP4 induce the activation of
the DNA damage response.
DISCUSSION
In sum, we have shown that during the G2 phase of the cell
division cycle, TFAP4 is targeted for degradation by the
SCFTrCP ubiquitin ligase. Notably, a genome-wide characteriza-
tion of TFAP4-controlled genes by mRNA profiling and DNA
binding analysis has been recently reported (2) and hundreds of
TFAP4 target genes, which are either induced or repressed by
TFAP4, have been identified.Gene ontology analysis revealed that
genes encoding cell cycle regulators were highly enriched among
the TFAP4-regulated genes suggesting that TrCP-dependent
degradation TFAP4 in G2 is required to modulate the expression
of a multitude of genes controlling cell cycle progression.
Evidence for overexpression of TFAP4 in colorectal, hepato-
cellular, and gastric carcinoma has been shown previously
(3–5). Our study, demonstrating that overexpression of wild
type TFAP4 and, more dramatically, the non-degradable
TFAP4 mutant, leads to aberrant mitotic division, suggests a
mechanism by which the misregulation of TFAP4 observed in
cancer may contribute to genomic instability and tumor pro-
gression. As mutations in c-MYC, a direct activator of TFAP4,
are frequent in cancer, an analysis of the occurrence of stabiliz-
ing and/or activating mutations in the TFAP4 gene in human
tumors should be warranted.
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